These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 33591799)

  • 1. MRI-defined high-risk rectal cancer patients: outcome comparison between neoadjuvant chemoradiotherapy plus TME and TME plus adjuvant chemotherapy or TME alone.
    Jia X; Xie P; Bi L; Meng X; Wang Z; Hong N; Wang Y
    Br J Radiol; 2021 Apr; 94(1120):20201221. PubMed ID: 33591799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI-defined T3, clear mesorectal fascia mid-low rectal cancer: is neoadjuvant treatment necessary?
    Zeng Z; Li Z; Luo S; Huang L; Liang Z; Zheng X; Li W; Xiong L; Liu H; Kang L
    J Gastroenterol Hepatol; 2024 May; 39(5):858-867. PubMed ID: 38225773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of neoadjuvant chemoradiotherapy combined with lateral lymph nodes dissection or not on the local recurrence of low to intermediate-stage II/III rectal cancer.
    Li C; Luan J; Ji X; Wang X; Li J; Li X; Zhou Y
    J Surg Oncol; 2024 Feb; 129(2):273-283. PubMed ID: 37811551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival outcomes of different neoadjuvant treatment regimens in patients with locally advanced rectal cancer and MRI-detected extramural venous invasion.
    Chen M; Ma Y; Song YW; Huang J; Gao YH; Zheng J; He F
    Cancer Med; 2023 Nov; 12(21):20523-20537. PubMed ID: 37864414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
    Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
    [No Abstract]   [Full Text] [Related]  

  • 6. Pretreatment MRI-detected extramural venous invasion as a prognostic and predictive biomarker for neoadjuvant chemoradiotherapy in non-metastatic rectal cancer: a propensity score matched analysis.
    Yang SY; Bae H; Seo N; Han K; Han YD; Cho MS; Hur H; Min BS; Kim NK; Lee KY; Lim JS
    Eur Radiol; 2024 Jun; 34(6):3686-3698. PubMed ID: 37994967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM Rectal Cancer Trial.
    Ruppert R; Junginger T; Ptok H; Strassburg J; Maurer CA; Brosi P; Sauer J; Baral J; Kreis M; Wollschlaeger D; Hermanek P; Merkel S;
    Br J Surg; 2018 Oct; 105(11):1519-1529. PubMed ID: 29744860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.
    Markovina S; Youssef F; Roy A; Aggarwal S; Khwaja S; DeWees T; Tan B; Hunt S; Myerson RJ; Chang DT; Parikh PJ; Olsen JR
    Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):417-426. PubMed ID: 28871992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer.
    Chen JN; Liu Z; Wang ZJ; Mei SW; Shen HY; Li J; Pei W; Wang Z; Wang XS; Yu J; Liu Q
    World J Gastroenterol; 2020 Jun; 26(21):2877-2888. PubMed ID: 32550762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center.
    Zhou J; Qiu H; Lin G; Xiao Y; Wu B; Wu W; Sun X; Lu J; Zhang G; Xu L; Liu Y
    Int J Colorectal Dis; 2016 Jun; 31(6):1163-8. PubMed ID: 27044403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI-detected tumor deposits in cT3 and cT4 rectal cancer following neoadjuvant chemoradiotherapy.
    Que YT; Chen Y; Yang XY; Ma YR; Liu YY; Wen ZQ; Lu BL; Wu XH; Zhang ZW; Wu YZ; Yu SP; Yuan JP
    Eur Radiol; 2024 May; 34(5):2963-2973. PubMed ID: 37840101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avoidance of Overtreatment of Rectal Cancer by Selective Chemoradiotherapy: Results of the Optimized Surgery and MRI-Based Multimodal Therapy Trial.
    Ruppert R; Kube R; Strassburg J; Lewin A; Baral J; Maurer CA; Sauer J; Junginger T; Hermanek P; Merkel S;
    J Am Coll Surg; 2020 Oct; 231(4):413-425.e2. PubMed ID: 32697965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low- Versus High-Risk Rectal Cancer Based on MRI Features: Outcomes in Patients Treated Without Neoadjuvant Chemoradiotherapy.
    Jia XX; Wang Y; Cheng J; Yao X; Yin MJ; Zhou J; Ye YJ
    AJR Am J Roentgenol; 2018 Aug; 211(2):327-334. PubMed ID: 29927331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
    [No Abstract]   [Full Text] [Related]  

  • 15. Preoperative lateral lymph node features and impact on local recurrence after neoadjuvant chemoradiotherapy and total mesorectal excision for locally advanced rectal cancer: results from a multicentre international cohort study.
    Achilli P; Ferrari D; Calini G; Bertoglio CL; Magistro C; Origi M; Carnevali P; Alampi BD; Giusti I; Ferrari G; Calafiore E; Spinelli A; Grass F; Deslarzes P; Hahnloser D; Abdalla S; Larson DW
    Colorectal Dis; 2024 Mar; 26(3):466-475. PubMed ID: 38243617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
    Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
    Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 18. Implication of MRI Risk Stratification System on the Survival Benefits of Adjuvant Chemotherapy After Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer.
    Zhao R; Zhao W; Zhu Y; Wan L; Chen S; Zhao Q; Zhao X; Zhang H
    Acad Radiol; 2023 Sep; 30 Suppl 1():S164-S175. PubMed ID: 37369619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lateral Nodal Features on Restaging Magnetic Resonance Imaging Associated With Lateral Local Recurrence in Low Rectal Cancer After Neoadjuvant Chemoradiotherapy or Radiotherapy.
    Ogura A; Konishi T; Beets GL; Cunningham C; Garcia-Aguilar J; Iversen H; Toda S; Lee IK; Lee HX; Uehara K; Lee P; Putter H; van de Velde CJH; Rutten HJT; Tuynman JB; Kusters M;
    JAMA Surg; 2019 Sep; 154(9):e192172. PubMed ID: 31268504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemoradiotherapy might provide survival benefit in patients with stage IIIb/IIIc locally advanced rectal cancer: A retrospective single-institution study with propensity score-matched comparative analysis.
    Sun XY; Cai SH; Xu L; Luo D; Qiu HZ; Wu B; Lin GL; Lu JY; Zhang GN; Xiao Y
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):142-149. PubMed ID: 32031326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.